Viridian raises $359M through equity and convertible debt to repay loans, fund R&D expansion

Noteholders can convert their bonds into common stock at $24.65 per share, representing a premium to current market price. Conversion is only allowed under specific conditions including when the stock price exceeds 130% of the conversion price for at least 20 trading days in a quarter, or during the final months before maturity in 2032.

If all notes are converted at the maximum conversion rate, up to 14.7 million new shares could be issued, representing potential dilution to existing shareholders. The actual dilution depends on whether the company settles conversions in cash, stock, or a combination.

If the company undergoes a major business combination or its stock is delisted, noteholders can force the company to buy back the notes at face value plus interest. This protects bondholders in change-of-control scenarios but could require significant cash outlay from the company.

The company disclosed the creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, cross-referencing Item 1.01 for details. Without the Item 1.01 text, the specific nature, amount, terms, and counterparties of the obligation cannot be determined from this excerpt.

Viridian issued $225 million in convertible notes, with underwriters exercising their full over-allotment option for an additional $25 million. The net proceeds were approximately $242.0 million after discounts and expenses. The offering closed on May 11, 2026.

The combined ~$359 million in proceeds will be used to fully repay existing debt with Hercules Capital from a 2022 loan agreement, fund market expansion studies for the company's thyroid eye disease franchise, advance R&D for earlier-stage pipeline programs, and support general corporate purposes. This represents a significant capital infusion to strengthen the balance sheet and accelerate commercial and development activities.

The equity offering includes a greenshoe option for underwriters to purchase up to an additional 1.1 million shares. This represents potential dilution of approximately 8.5 million shares total (base plus option) for existing shareholders, though the filing does not indicate whether the option was exercised.

Viridian will use a portion of the offering proceeds to fully retire its debt facility with Hercules Capital that originated in April 2022. This eliminates debt obligations and associated interest expense, improving the company's financial flexibility.

Viridian entered into an underwriting agreement on May 6, 2026 for an equity offering with Jefferies, Leerink Partners, and Goldman Sachs as underwriters. This represents a capital raise through the sale of common stock, though specific terms like share count and pricing are not disclosed in this 8-K.

Viridian simultaneously entered into a separate underwriting agreement on May 6, 2026 for a convertible notes offering with the same underwriter syndicate. This represents debt financing that can convert to equity under specified conditions.

Viridian issued convertible senior notes with a 1.75% coupon rate maturing in 2032. These notes provide holders the option to convert into Viridian common stock at predetermined terms, offering downside protection through fixed income with equity upside potential. The low coupon rate reflects the value of the conversion feature to investors.

Viridian established a base indenture agreement with U.S. Bank Trust Company as trustee on May 11, 2026, governing the terms and administration of the convertible notes. This legal framework defines bondholder rights, company obligations, and trustee responsibilities for the debt issuance.